Graft-versus-host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience

Br J Haematol. 2001 Apr;113(1):251-3. doi: 10.1046/j.1365-2141.2001.02734.x.

Abstract

The effect of ABO-incompatibility on graft versus host disease (GVHD) and survival was evaluated in 173 consecutive patients receiving allogeneic bone marrow transplantation (BMT). Thirty-four percent of the patients developed GVHD and univariate analysis suggested a higher incidence of GVHD in minor ABO-incompatibility than in ABO-identity (14/30, 47% versus 37/112, 33%; P = 0.02). However, using logistic regression adjusted for potential confounders, the GVHD risk did not differ significantly. During a mean follow-up time of 59 months, the mortality was 37% and survival was significantly dependent on ABO-compatibility (P = 0.004). In particular, patients with bidirectional ABO-incompatibility had an excess mortality rate (RR, 7.6; 95% CI, 2.5-23.2; P = 0.0004). Taken together, these results suggest that ABO-incompatibility may represent a risk factor in allogeneic BMT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ABO Blood-Group System
  • Acute Disease
  • Adolescent
  • Adult
  • Blood Group Incompatibility*
  • Bone Marrow Transplantation / mortality*
  • Child
  • Child, Preschool
  • Female
  • Graft vs Host Disease / etiology*
  • Graft vs Host Disease / mortality
  • Humans
  • Leukemia / mortality
  • Leukemia / therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • Leukemia, Myeloid / mortality
  • Leukemia, Myeloid / therapy
  • Male
  • Middle Aged
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Regression Analysis
  • Risk Factors
  • Survival Rate
  • Transplantation, Homologous

Substances

  • ABO Blood-Group System